BARDA is expanding its existing partnership with DiaSorin SpA on the development of a COVID-19 immunoassay. This new test detects the presence of SARS-CoV-2 in nasal swabs or nasopharyngeal swabs to diagnose acute COVID-19 disease.
DiaSorin intends to develop, validate, manufacture, market, and obtain regulatory authorization in the United States and worldwide for this new, fully automated, chemiluminescent, antigen assay for the qualitative detection of the SARS-CoV-2 virus using nasal swabs or nasopharyngeal swabs. This assay will allow testing of nasal swabs in addition to traditional nasopharyngeal swabs, thereby expanding the utility of the assay by simplifying collection and enhancing patient comfort and safety.
This test is being designed to determine if an individual is experiencing acute SARS-CoV-2 infection by detecting the presence of the N protein of the virus in multiple clinical samples. The LIAISON XL platform allows laboratories to process up to 136 patient samples per hour, with a minimum level of intervention required by laboratory operators. Individual lab-based test results can reach healthcare providers in under three hours.
About DiaSorin SpA:
The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.
DiaSorin is a global leader in the laboratory diagnostics market, specializing in the immunodiagnostics and molecular diagnostics segments. For over 50 years DiaSorin Group has been developing, producing and commercializing diagnostic tests. DiaSorin supports clinical laboratory needs and activities, providing solutions that are reliable, innovative, fully automated and standardized. DiaSorin continually invests in Research & Development, using distinctive expertise in the field to deliver a high level of innovation. More information is available at: https://www.diasorin.com.